Tsai CY, et al. - This study was sought to evaluate the efficacy and safety of teicoplanin vs β-lactam for febrile patients with Staphylococcus -like bacteremia. Researchers enrolled 84 adults with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia: initial teicoplanin treatment group (n = 28) and β-lactam treatment group (n = 56). The clinical outcomes between the groups before and after propensity score matching after treatment completion were tested. No significant difference was observed in clinical outcomes between initial teicoplanin treatment and β-lactam treatment among patients with MSSA bacteremia. It was shown that the Pittsburgh bacteremia score ≥ 4 was a significant risk factor for mortality.